Skip to main content

Peer Review reports

From: Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study

Original Submission
6 Jul 2023 Submitted Original manuscript
21 Aug 2023 Reviewed Reviewer Report
23 Oct 2023 Reviewed Reviewer Report
21 Nov 2023 Author responded Author comments - Xuelian Liao
23 Nov 2023 Author responded Author comments - Xuelian Liao
Resubmission - Version 2
21 Nov 2023 Submitted Manuscript version 2
30 Nov 2023 Reviewed Reviewer Report
11 Dec 2023 Reviewed Reviewer Report
28 Dec 2023 Author responded Author comments - Xuelian Liao
Resubmission - Version 3
28 Dec 2023 Submitted Manuscript version 3
29 Dec 2023 Author responded Author comments - Xuelian Liao
Resubmission - Version 4
29 Dec 2023 Submitted Manuscript version 4
6 Jan 2024 Reviewed Reviewer Report
22 Jan 2024 Author responded Author comments - Xuelian Liao
Resubmission - Version 5
22 Jan 2024 Submitted Manuscript version 5
27 Jan 2024 Reviewed Reviewer Report
10 Feb 2024 Author responded Author comments - Xuelian Liao
Resubmission - Version 6
10 Feb 2024 Submitted Manuscript version 6
12 Feb 2024 Author responded Author comments - Xuelian Liao
Resubmission - Version 7
12 Feb 2024 Submitted Manuscript version 7
16 Feb 2024 Reviewed Reviewer Report
Resubmission - Version 8
Submitted Manuscript version 8
Publishing
17 Feb 2024 Editorially accepted
18 Jun 2024 Article published 10.1186/s12879-024-09150-1

You can find further information about peer review here.

Back to article page